These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

89 related items for PubMed ID: 20839949

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomas.
    Lo SS, Khorana AA, Javle M, Simon S, Kiefer G, Rajasenan K, Wang H, Hantel A, Shayne M, Hwang J, Schmotzer A, Ramanathan RK.
    Oncology; 2010; 78(2):125-9. PubMed ID: 20389134
    [Abstract] [Full Text] [Related]

  • 4. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
    Sym SJ, Ryu MH, Kang HJ, Lee SS, Chang HM, Lee JL, Kim TW, Yook JH, Oh ST, Kim BS, Kang YK.
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
    [Abstract] [Full Text] [Related]

  • 5. A phase I study of docetaxel, oxaliplatin, and capecitabine in patients with metastatic gastroesophageal cancer.
    Evans D, Miner T, Akerman P, Millis R, Jean M, Kennedy T, Safran H.
    Am J Clin Oncol; 2007 Aug; 30(4):346-9. PubMed ID: 17762433
    [Abstract] [Full Text] [Related]

  • 6. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
    Spigel DR, Greco FA, Meluch AA, Lane CM, Farley C, Gray JR, Clark BL, Burris HA, Hainsworth JD.
    J Clin Oncol; 2010 May 01; 28(13):2213-9. PubMed ID: 20351330
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. New recommendation of doses in an ongoing phase II study of docetaxel, oxaliplatin and capecitabine as first line therapy in advanced gastro-oesophageal cancer.
    Schønnemann KR, Yilmaz M, Andersen M, Pfeiffer P.
    Acta Oncol; 2011 Jan 01; 50(1):151-2. PubMed ID: 20843172
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma.
    Goel G, Jauhri M, Negi A, Aggarwal S.
    Hematol Oncol Stem Cell Ther; 2010 Jan 01; 3(2):55-9. PubMed ID: 20543537
    [Abstract] [Full Text] [Related]

  • 11. Phase I study of oxaliplatin in combination with capecitabine and radiotherapy as postoperative treatment for stage II and III rectal cancer.
    Jin J, Li YX, Wang JW, Wang WH, Liu YP, Wang K, Fang H, Zhou ZX, Zhou AP, Yu ZH.
    Int J Radiat Oncol Biol Phys; 2008 Nov 01; 72(3):671-7. PubMed ID: 18455328
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Oxaliplatin and capecitabine-based chemoradiotherapy for gastric cancer--an extended phase I MARGIT and AIO trial.
    Hofheinz RD, Wenz F, Lukan N, Mai S, Kripp M, Staiger W, Schwarzbach M, Willeke F, Möhler M, Post S, Hochhaus A.
    Int J Radiat Oncol Biol Phys; 2009 Jan 01; 73(1):142-7. PubMed ID: 18539404
    [Abstract] [Full Text] [Related]

  • 14. Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: results of a multicenter phase I/II study.
    Stein A, Arnold D, Thuss-Patience PC, Moehler M, Grothe W, Seufferlein T, Reinacher-Schick A, Geissler M, Hofheinz RD, Schmoll HJ.
    Acta Oncol; 2014 Mar 01; 53(3):392-8. PubMed ID: 24024696
    [Abstract] [Full Text] [Related]

  • 15. Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer.
    Di Lauro L, Vici P, Belli F, Tomao S, Fattoruso SI, Arena MG, Pizzuti L, Giannarelli D, Paoletti G, Barba M, Sergi D, Maugeri-Saccà M.
    Gastric Cancer; 2014 Oct 01; 17(4):718-24. PubMed ID: 24318671
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Phase II study of weekly intravenous oxaliplatin combined with oral daily capecitabine and radiotherapy with biologic correlates in neoadjuvant treatment of rectal adenocarcinoma.
    Fakih MG, Bullarddunn K, Yang GY, Pendyala L, Toth K, Andrews C, Rustum YM, Ross ME, Levea C, Puthillath A, Park YM, Rajput A.
    Int J Radiat Oncol Biol Phys; 2008 Nov 01; 72(3):650-7. PubMed ID: 18565686
    [Abstract] [Full Text] [Related]

  • 18. Docetaxel, capecitabine and carboplatin in metastatic esophagogastric cancer: a phase II study.
    Evans D, Miner T, Iannitti D, Akerman P, Cruff D, Maia-Acuna C, Harrington D, Habr F, Chauhan B, Berkenblit A, Stuart K, Sears D, Kennedy T, Safran H.
    Cancer Invest; 2007 Sep 01; 25(6):445-8. PubMed ID: 17882656
    [Abstract] [Full Text] [Related]

  • 19. Dose escalation study on oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumors.
    Kakolyris S, Souglakos J, Kouroussis C, Androulakis N, Samonis G, Vardakis N, Amarantidis K, Agelaki S, Mavroudis D, Xenidis N, Georgoulias V.
    Oncology; 2004 Sep 01; 66(4):253-9. PubMed ID: 15218291
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.